Hormones should be administered at the lowest effective dose and for the shortest duration possible. If prolonged use of low-dose corticosteroids is necessary, patients should undergo continuous monitoring to mitigate potential adverse events.
Cumulative corticosteroid dosage was significantly associated with the risk of serious adverse events. The higher the cumulative dose of hormones, the higher the risk of these outcomes. Patients should be closely monitored for cumulative hormone dosage and avoid overdose.
Patients with diabetes or prediabetes should minimize hormone use whenever feasible. Those with chronic kidney disease or a history of gastrointestinal bleeding should attempt to steer clear of non-steroidal anti-inflammatory pain relievers.
Patients receiving rheumatology medications should undergo regular monitoring for any changes in their condition, drug reactions, and the occurrence of adverse effects.
Particularly for individuals on long-term hormone or disease-modifying antirheumatic drugs (DMARDs), parameters such as blood tests, liver and kidney function, etc., should be closely observed.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1572025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1552025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1702024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1602024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1452024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2472024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: